Scholarlink

<p>Predicting prognosis using baseline clinical and genetic features remains critical in the tyrosine-kinase-inhibitor (TKI) era of chronic myeloid leukemia (CML). We retrospectively analyzed 944 chronic phase CML (CML-CP) patients treated at a single center in China, aiming to clarify treatment responses, long-term outcomes and baseline prognostic factors in real-world settings. Analyses were performed in available patient subsets depending on endpoint-specific data completeness. The study found that female patients had higher major molecular response (MMR) than males (<i>P =</i> 0.004). Age ≥ 45 years was associated with lower complete cytogenetic response (CCyR; <i>p</i> = 0.006), overall survival (OS; <i>p</i> = 0.011), and CML-related survival (<i>p</i> = 0.010). Initial white-blood-cell counts ≥ 118 × 10⁹/L predicted inferior CCyR and MMR (both <i>P &lt;</i> 0.001). Conversely, baseline haemoglobin ≥ 110&#xa0;g/L independently predicted superior CCyR, MMR (both <i>P &lt;</i> 0.001), event-free survival (EFS; <i>p</i> = 0.009), progression-free survival (PFS; <i>p</i> = 0.008), OS (<i>P =</i> 0.001), and CML-related survival (<i>p</i> = 0.001). Compared to patients without ACAs, high-risk additional chromosomal abnormalities (HR-ACAs) conferred worse EFS (<i>P =</i> 0.042), PFS (<i>P =</i> 0.057), OS (<i>P =</i> 0.010) and CML-related survival (<i>P =</i> 0.006). Gender and initial WBC primarily influenced TKI treatment responses, while age and initial Hgb levels influenced both TKI responses and long-term survival. Additionally, HR-ACAs significantly predicted poorer long-term survival in CML-CP patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Qingyuan Wang,
  • Yucheng Jiang,
  • Xiangyu Zhao,
  • Yiyan Zhu,
  • Zhao Zeng,
  • Xiaofei Yang,
  • Qian Wu,
  • Jinlan Pan,
  • Li Yao,
  • Jiannong Cen,
  • Suning Chen,
  • Mengxing Xue

摘要

Predicting prognosis using baseline clinical and genetic features remains critical in the tyrosine-kinase-inhibitor (TKI) era of chronic myeloid leukemia (CML). We retrospectively analyzed 944 chronic phase CML (CML-CP) patients treated at a single center in China, aiming to clarify treatment responses, long-term outcomes and baseline prognostic factors in real-world settings. Analyses were performed in available patient subsets depending on endpoint-specific data completeness. The study found that female patients had higher major molecular response (MMR) than males (P = 0.004). Age ≥ 45 years was associated with lower complete cytogenetic response (CCyR; p = 0.006), overall survival (OS; p = 0.011), and CML-related survival (p = 0.010). Initial white-blood-cell counts ≥ 118 × 10⁹/L predicted inferior CCyR and MMR (both P < 0.001). Conversely, baseline haemoglobin ≥ 110 g/L independently predicted superior CCyR, MMR (both P < 0.001), event-free survival (EFS; p = 0.009), progression-free survival (PFS; p = 0.008), OS (P = 0.001), and CML-related survival (p = 0.001). Compared to patients without ACAs, high-risk additional chromosomal abnormalities (HR-ACAs) conferred worse EFS (P = 0.042), PFS (P = 0.057), OS (P = 0.010) and CML-related survival (P = 0.006). Gender and initial WBC primarily influenced TKI treatment responses, while age and initial Hgb levels influenced both TKI responses and long-term survival. Additionally, HR-ACAs significantly predicted poorer long-term survival in CML-CP patients.